Carmat - Update on EFICAS and FY24 guidance reiterated
20 patients implanted so far in the EFICAS study – 9 in FY24. Carmat is on track to reach its target of 30 implants in '24. Interim results from 6 patients show 75% success rate, beating management expectations and past studies results.Based on progress made so far and the 39 hospitals trained for commercial implants, management reiterates FY24 sales guidance of c. EUR 14m. Cash runway until end of May (vs. mid-May previously). Carmat indicates that some reference shareholders already confirmed their financial support in the ST.Financing remains a short-term concern as the company has less than 1 months ofCarmat is focused on the research and development of an innovative product in the medical sector, developing an orthotopic and biocompatible artificial heart which is completely implantable, as well as its electrical power supply system and remote diagnosis system. Co. is developing a long-term therapeutic solution for patients who suffer from advanced bi-ventricular heart failure and who are not eligible for cardiac transplantation and who have exhausted all drug possibilties. Co. is still in the phase of research and development and thus do not generate any revenues.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.